12/20
07:36 am
dnth
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
Low
Report
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
12/14
05:49 am
dnth
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) was upgraded by analysts at Raymond James to a "moderate buy" rating.
Low
Report
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) was upgraded by analysts at Raymond James to a "moderate buy" rating.
11/11
10:22 am
dnth
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Low
Report
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
11/11
09:02 am
dnth
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its price target raised by analysts at Oppenheimer Holdings Inc. from $48.00 to $52.00. They now have an "outperform" rating on the stock.
High
Report
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its price target raised by analysts at Oppenheimer Holdings Inc. from $48.00 to $52.00. They now have an "outperform" rating on the stock.
11/8
01:45 pm
dnth
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its price target raised by analysts at Raymond James from $51.00 to $56.00. They now have an "outperform" rating on the stock.
Low
Report
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its price target raised by analysts at Raymond James from $51.00 to $56.00. They now have an "outperform" rating on the stock.
11/7
07:48 pm
dnth
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Low
Report
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
11/7
04:01 pm
dnth
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
Low
Report
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
11/4
07:00 am
dnth
Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences
Low
Report
Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences
10/15
07:00 am
dnth
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting
High
Report
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting
10/3
08:17 am
dnth
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $48.00 price target on the stock.
Medium
Report
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $48.00 price target on the stock.